KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

HRV Pharma, Shodhana join hands to build next-gen API pipeline for global markets

Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets

Enveric Biosciences bags key US patent for mental health drug

EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes

Experts advocate holistic Semaglutide use as therapy goes off patent in India

They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market

Kauvery Hospital sets new benchmark in high-risk cardiac care

71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day

Apollo Hospitals hosts specialist dialogue on vertigo diagnosis challenges

Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy

The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions

Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume